+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Acute Lung Injury Treatment Market - Global Forecast 2026-2032- Product Image
Acute Lung Injury Treatment Market - Global Forecast 2026-2032- Product Image
New

Acute Lung Injury Treatment Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 192 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6015132
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The acute lung injury treatment market is experiencing steady evolution as clinical innovation, supply chain resilience, and care delivery models transform therapy access and outcomes. Senior stakeholders navigating this sector require actionable, evidence-driven insights to set successful strategy amid shifting global and regulatory landscapes.

Market Snapshot: Acute Lung Injury Treatment Market

The Acute Lung Injury Treatment Market grew from USD 3.36 billion in 2025 to USD 3.52 billion in 2026. It is expected to continue growing at a CAGR of 4.30%, reaching USD 4.52 billion by 2032.

Scope & Segmentation

This report examines the full spectrum of the acute lung injury treatment market, covering multiple therapeutic, operational, and regional factors driving clinical and commercial decision-making.

  • Drug Classes: Includes corticosteroids such as dexamethasone, hydrocortisone, and methylprednisolone; neuromuscular blocking agents like cisatracurium, rocuronium, and vecuronium; surfactants—including beractant and poractant alfa; and vasodilators, notably inhaled nitric oxide.
  • Administration Routes: Focus on inhalation and intravenous approaches, considering implications for speed of onset, targeted delivery, and clinical suitability across patient subgroups.
  • End Users & Care Settings: Analysis spans hospitals, ambulatory care centers, research institutes, and key clinical environments: emergency departments, intensive care units, and general wards.
  • Patient Age Groups: Adult, geriatric, and pediatric cohorts, emphasizing formulation, dosing, and safety nuances for each group.
  • Distribution Channels: Evaluation of hospital pharmacies, retail pharmacies (chain and independent), and online direct-to-patient models impacting treatment access and procurement practices.
  • Regional Analysis: Coverage includes Americas, Europe Middle East & Africa, and Asia-Pacific, detailing how infrastructure, regulation, and local health priorities shape adoption and access.
  • Technological Innovation: Review of advancements in inhalation systems, remote monitoring, tele-ICU solutions, and platform manufacturing for complex biologics and reformulations.

Key Takeaways for Senior Decision-Makers

  • The ongoing shift toward more precise, stratified clinical approaches enables tailored treatment—but also increases complexity in decision-making and evidence requirements for market entry.
  • Technology deployment, such as enhanced pulmonary delivery and integrated monitoring, is redefining therapeutic value and creating new competitive benchmarks beyond traditional efficacy endpoints.
  • Operational challenges, including regulatory change and supply chain disruptions, underscore the strategic importance of resilient sourcing, manufacturing diversity, and dynamic inventory planning.
  • Stakeholder expectations are rising: Payers and health systems prioritize interventions that demonstrate system-level benefits and resource efficiency, influencing both procurement and adoption patterns.
  • Integrated product-partnership strategies—combining drug, device, and service elements—are fast emerging as a differentiator, accelerating real-world evidence generation and guideline inclusion.

Tariff Impact on the Acute Lung Injury Treatment Market

Trade policy adjustments up to 2025 have reshaped procurement, supplier relationships, and inventory management. Supply chain resilience has become central, driving trends such as nearshoring, supplier diversification, and strategic stockpiling. Market participants increasingly emphasize flexibility in manufacturing footprints and distribution networks to reduce risk, supporting uninterrupted therapy availability across care settings.

Methodology & Data Sources

This report is grounded in structured interviews with key clinical, operational, and regulatory experts. Findings are synthesized with robust secondary research, including peer-reviewed literature and up-to-date guidelines. Triangulation and expert feedback ensure relevance to frontline realities across all key segments.

Why This Report Matters

  • Enables optimized investment and commercial planning by clarifying drivers of clinical adoption and supply resilience across global markets.
  • Supports product portfolio and partnership decisions by mapping nuanced segmentation against technology trends and real-world evidence needs.
  • Provides a validated, actionable foundation for aligning clinical, regulatory, and operational strategy in a complex, evolving landscape.

Conclusion

The acute lung injury treatment sector is transforming as innovation, operational agility, and stakeholder collaboration define future value. Effective strategy hinges on integrating clinical, supply, and regulatory perspectives to ensure sustained therapeutic adoption and improved patient outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Acute Lung Injury Treatment Market, by Drug Class
8.1. Corticosteroids
8.1.1. Dexamethasone
8.1.2. Hydrocortisone
8.1.3. Methylprednisolone
8.2. Neuromuscular Blocking Agents
8.2.1. Cisatracurium
8.2.2. Rocuronium
8.2.3. Vecuronium
8.3. Surfactants
8.3.1. Beractant
8.3.2. Poractant Alfa
8.4. Vasodilators
9. Acute Lung Injury Treatment Market, by Administration Route
9.1. Inhalation
9.2. Intravenous
10. Acute Lung Injury Treatment Market, by Patient Age Group
10.1. Adult
10.2. Geriatric
10.3. Pediatric
11. Acute Lung Injury Treatment Market, by Treatment Setting
11.1. Emergency Department
11.2. General Ward
11.3. Intensive Care Unit
12. Acute Lung Injury Treatment Market, by End User
12.1. Ambulatory Care Centers
12.2. Hospitals
12.3. Research Institutes
13. Acute Lung Injury Treatment Market, by Distribution Channel
13.1. Hospital Pharmacies
13.1.1. Inpatient Pharmacies
13.1.2. Outpatient Pharmacies
13.2. Online Pharmacies
13.2.1. Direct To Patient
13.2.2. Third Party Fulfillment
13.3. Retail Pharmacies
13.3.1. Chain Pharmacies
13.3.2. Independent Pharmacies
14. Acute Lung Injury Treatment Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Acute Lung Injury Treatment Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Acute Lung Injury Treatment Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Acute Lung Injury Treatment Market
18. China Acute Lung Injury Treatment Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. AstraZeneca PLC
19.6. Bayer AG
19.7. BioLineRx Ltd.
19.8. Boehringer Ingelheim GmbH
19.9. Chiesi Farmaceutici S.p.A.
19.10. CSL Behring LLC.
19.11. Eli Lilly and Company
19.12. FibroGen, Inc.
19.13. Genentech, Inc.
19.14. Gilead Sciences, Inc.
19.15. GlaxoSmithKline plc
19.16. Hoffmann-La Roche Ltd.
19.17. Lisata Therapeutics, Inc.
19.18. Merck & Co., Inc.
19.19. Mesoblast Limited
19.20. Novartis International AG
19.21. Pfizer Inc.
19.22. Regeneron Pharmaceuticals, Inc.
19.23. Sanofi S.A.
19.24. Synairgen plc
19.25. Takeda Pharmaceutical Company Limited
19.26. Windtree Therapeutics, Inc.
List of Figures
FIGURE 1. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HYDROCORTISONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CISATRACURIUM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ROCURONIUM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VECURONIUM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BERACTANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PORACTANT ALFA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VASODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EMERGENCY DEPARTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GENERAL WARD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTENSIVE CARE UNIT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INPATIENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OUTPATIENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIRECT TO PATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY THIRD PARTY FULFILLMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 114. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
TABLE 115. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
TABLE 116. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 117. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 118. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 119. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 122. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 123. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 126. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
TABLE 128. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 131. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 135. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 139. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 140. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
TABLE 141. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
TABLE 142. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 147. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 148. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 163. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 164. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 165. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 166. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
TABLE 167. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
TABLE 168. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 169. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 170. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 171. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 172. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 174. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 175. EUROPE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 176. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 177. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 178. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 182. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 183. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 184. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 187. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 188. MIDDLE EAST ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 189. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 191. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 192. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
TABLE 193. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
TABLE 194. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 195. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 196. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 197. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 198. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 199. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 200. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 201. AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 202. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 203. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 204. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 205. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
TABLE 206. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
TABLE 207. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 208. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 209. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 210. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 211. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 212. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 213. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 214. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 215. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 216. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 218. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 219. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
TABLE 220. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
TABLE 221. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 222. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 223. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 224. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 225. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 226. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 227. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 228. ASEAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 229. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 230. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 231. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 232. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
TABLE 233. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
TABLE 234. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 235. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 236. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 237. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 238. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 239. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 240. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 241. GCC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 252. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 253. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 254. EUROPEAN UNION ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 255. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 256. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 257. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 258. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
TABLE 259. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
TABLE 260. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 261. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 262. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 263. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 264. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 265. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 266. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 267. BRICS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 268. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 269. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 270. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 271. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
TABLE 272. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
TABLE 273. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 274. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 275. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 276. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 277. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 278. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 279. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 280. G7 ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 281. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 282. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 283. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 284. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
TABLE 285. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
TABLE 286. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 287. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 288. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 289. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 290. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 291. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 292. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
TABLE 293. NATO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 294. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 295. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 296. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 297. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 298. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NEUROMUSCULAR BLOCKING AGENTS, 2018-2032 (USD MILLION)
TABLE 299. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURFACTANTS, 2018-2032 (USD MILLION)
TABLE 300. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 301. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 302. U

Companies Mentioned

The key companies profiled in this Acute Lung Injury Treatment market report include:
  • AstraZeneca PLC
  • Bayer AG
  • BioLineRx Ltd.
  • Boehringer Ingelheim GmbH
  • Chiesi Farmaceutici S.p.A.
  • CSL Behring LLC.
  • Eli Lilly and Company
  • FibroGen, Inc.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hoffmann-La Roche Ltd.
  • Lisata Therapeutics, Inc.
  • Merck & Co., Inc.
  • Mesoblast Limited
  • Novartis International AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Synairgen plc
  • Takeda Pharmaceutical Company Limited
  • Windtree Therapeutics, Inc.

Table Information

Report AttributeDetails
No. of Pages192
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.52 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.52 Billion
Compound Annual Growth Rate4.3%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Acute Lung Injury Market Report 2025 - Product Image

Acute Lung Injury Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Acute Lung Injury - Pipeline Insight, 2025 - Product Image

Acute Lung Injury - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Acute Respiratory Distress Syndrome Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis - Product Image

Acute Respiratory Distress Syndrome Treatment Market Outlook 2026-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Acute Respiratory Distress Syndrome (ARDS) - Pipeline Insight, 2025 - Product Image

Acute Respiratory Distress Syndrome (ARDS) - Pipeline Insight, 2025

  • Clinical Trials
  • 100 Pages
  • Global
From
Global Acute Respiratory Distress Syndrome (ARDS) Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Global Acute Respiratory Distress Syndrome (ARDS) Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 130 Pages
  • Global
From

About the Lung Injury Drug Market

The Lung Injury Drug market is a subset of the larger Respiratory Drugs market, which includes treatments for a variety of respiratory conditions such as asthma, COPD, and cystic fibrosis. Lung Injury Drugs are specifically designed to treat acute lung injury, a condition that can be caused by a variety of factors, including infection, trauma, and environmental toxins. These drugs are typically administered intravenously and can help reduce inflammation, improve oxygenation, and reduce the risk of further lung damage. The Lung Injury Drug market is highly competitive, with a number of companies offering products that target different aspects of the condition. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Novartis, Merck, and Pfizer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.